Infection and non infection complications post lung transplant
Reading File
Searching for infectious and non-infectious complications following lung transplantation in parallel.
search_medical_text
infectious complications after lung transplant bacterial fungal viral
Harrison's Principles of Internal Medicine, Twenty First Edition
Page 8149
search_medical_text
non-infectious complications lung transplant rejection bronchiolitis obliterans primary graft dysfunction
Harrison's Principles of Internal Medicine, Twenty First Edition
Page 8148
GradeResponse
GradeResponse
Here is a comprehensive overview of post-lung transplant complications:
Complications After Lung Transplantation
Lung transplantation carries significant risks for both infectious and non-infectious complications. The lung is uniquely vulnerable among solid organs because it is in continuous contact with the environment, and the transplanted lung has impaired mucociliary clearance and reduced lymphatic function (Harrison's, p. 8149).
NON-INFECTIOUS COMPLICATIONS
1. Primary Graft Dysfunction (PGD)
The most common cause of early morbidity and mortality after transplant (Harrison's, p. 8148).
- Mechanism: Ischemia-reperfusion injury to the allograft (not infection or rejection)
- Presentation: Diffuse bilateral infiltrates on CXR + poor gas exchange
- Diagnosis: PaO₂:FiO₂ ratio < 300 within 72 hours of transplant
- Severe PGD = diffuse severe infiltrates + profound hypoxemia
- Management: Lung-protective ventilation, prone positioning, ECMO in refractory cases
2. Hyperacute Rejection
- Extremely rare due to pre-transplant ABO and HLA compatibility screening
- Antibody-mediated destruction of the graft within minutes to hours
3. Acute Cellular Rejection (ACR)
- Typically occurs in the first year
- Perivascular and peribronchiolar lymphocytic infiltration
- Presentation: Fever, dyspnea, hypoxia, new infiltrates
- Diagnosis: Transbronchial biopsy (graded A0–A4)
- Treatment: High-dose IV methylprednisolone pulse
4. Antibody-Mediated Rejection (AMR)
- Driven by donor-specific antibodies (DSAs)
- Harder to diagnose; associated with worse outcomes
- Treatment: Plasmapheresis, IVIG, rituximab, bortezomib
5. Chronic Lung Allograft Dysfunction (CLAD)
The leading cause of late mortality after lung transplant. Two main phenotypes:
| Feature | Bronchiolitis Obliterans Syndrome (BOS) | Restrictive Allograft Syndrome (RAS) |
|---|---|---|
| Pattern | Obstructive | Restrictive |
| FEV₁ decline | Yes | Yes |
| CT findings | Air trapping, mosaic attenuation | Peripheral/upper lobe fibrosis, pleuroparenchymal involvement |
| Prognosis | Poor | Worse than BOS |
| Treatment | Azithromycin, augmenting immunosuppression | Limited; pirfenidone investigated |
- BOS is defined as a persistent decline in FEV₁ ≥ 20% from baseline
- Risk factors include ACR, lymphocytic bronchiolitis, infections, GERD, and HLA mismatch
6. Airway Complications
- Anastomotic dehiscence: Early complication; due to ischemia at bronchial anastomosis
- Bronchial stenosis: Late complication; may require bronchoscopic dilation or stenting
- Bronchomalacia: Airway collapse due to cartilage destruction
7. Pleural Complications
- Pleural effusions (common post-operatively)
- Pneumothorax
- Chylothorax (lymphatic disruption)
- Hemothorax
8. Cardiovascular Complications
- Atrial arrhythmias (very common early; especially atrial flutter/fibrillation)
- Systemic hypertension (calcineurin inhibitor effect)
- Pulmonary hypertension of the native lung (in single-lung recipients)
9. Renal Dysfunction
- Calcineurin inhibitors (tacrolimus, cyclosporine) cause nephrotoxicity
- Up to 30% of recipients develop chronic kidney disease; ~5% require dialysis
10. Gastrointestinal Complications
- GERD is both a complication and a risk factor for CLAD (bile acid microaspiration damages the allograft)
- Gastroparesis, bowel dysmotility (especially in cystic fibrosis patients)
11. Malignancy
- Post-transplant lymphoproliferative disorder (PTLD): EBV-driven B-cell proliferation; higher risk with EBV mismatch
- Non-melanoma skin cancers: Most common solid organ malignancy post-transplant
- Lung cancer: Risk in the remaining native lung (especially in emphysema/COPD patients)
12. Metabolic Complications
- Diabetes mellitus (new-onset or worsening; corticosteroids + tacrolimus)
- Osteoporosis and fractures
- Hyperlipidemia (sirolimus, corticosteroids)
INFECTIOUS COMPLICATIONS
The highest incidence of infection occurs early post-transplant, coinciding with peak immunosuppression intensity (Harrison's, p. 8149).
Timeline Framework
| Period | Timeframe | Common Infections |
|---|---|---|
| Early | 0–1 month | Bacterial (gram-negative), surgical site, mediastinitis, UTI, line sepsis |
| Middle | 1–6 months | CMV, PJP, fungal (Aspergillus, Candida), viral (EBV, HCV) |
| Late | > 6 months | Community-acquired infections, chronic viral, BOS-associated bacterial colonization |
Bacterial Infections
- Gram-negative bacilli (Pseudomonas, Klebsiella, Enterobacter) predominate early
- Pneumonia is the most common serious bacterial infection
- Other manifestations: mediastinitis, UTI, catheter-related bloodstream infections, wound infections
- Pre-transplant colonization organisms (especially in CF patients with Burkholderia cepacia complex or MRSA) can cause post-transplant infections
- Perioperative prophylaxis is tailored to the donor and recipient's pre-transplant microbiology
Viral Infections
| Virus | Clinical Significance |
|---|---|
| CMV | Most important; causes pneumonitis, GI disease, retinitis; also triggers CLAD |
| EBV | Risk of PTLD |
| RSV / Influenza / Parainfluenza | Community-acquired; can trigger CLAD exacerbations |
| Adenovirus | Severe pneumonitis |
| COVID-19 | Associated with high mortality and CLAD progression |
| HSV / VZV | Reactivation; prophylaxis with acyclovir/valacyclovir |
- CMV mismatch (donor seropositive, recipient seronegative = D+/R−) = highest-risk combination
- Prophylaxis: valganciclovir; surveillance with CMV PCR
Fungal Infections
| Organism | Notes |
|---|---|
| Aspergillus spp. | Most significant fungal pathogen; tracheobronchitis, invasive pulmonary aspergillosis, anastomotic infection |
| Candida spp. | Surgical site and bloodstream infections |
| Pneumocystis jirovecii (PJP) | Universal prophylaxis with TMP-SMX; risk highest in first 6 months |
| Cryptococcus | Meningitis, pulmonary disease |
| Endemic fungi | Histoplasma, Coccidioides, Blastomyces in relevant geographic areas |
- Aspergillus is particularly dangerous due to bronchial anastomosis proximity
- Prophylaxis: inhaled amphotericin B or oral voriconazole/itraconazole
Mycobacterial Infections
- NTM (Non-tuberculous mycobacteria): Mycobacterium abscessus is particularly problematic in CF patients
- Reactivation of latent TB can occur; LTBI screening and treatment before transplant is critical
SUMMARY: Complications by Time Post-Transplant
| Phase | Non-Infectious | Infectious |
|---|---|---|
| Immediate (0–72h) | PGD, hyperacute rejection, hemothorax | Donor-derived infections |
| Early (1–4 weeks) | ACR, airway dehiscence, arrhythmias | Bacterial pneumonia, mediastinitis, UTI |
| Middle (1–6 months) | ACR, renal dysfunction, diabetes | CMV, PJP, Aspergillus, EBV/PTLD |
| Late (> 6 months) | CLAD (BOS/RAS), malignancy, osteoporosis | Community-acquired, NTM, chronic CMV |
Lung transplant recipients require lifelong immunosuppression (typically a triple regimen of a calcineurin inhibitor + antimetabolite + corticosteroid), which underlies essentially all the infectious complications and many of the non-infectious ones. The balance between preventing rejection and avoiding over-immunosuppression is the central challenge of long-term management.
Give me along with drug dosage
search_medical_text
lung transplant infection prophylaxis treatment drug dosage CMV bacterial fungal
Harrison's Principles of Internal Medicine, Twenty First Edition
Page 8149
search_medical_text
lung transplant rejection treatment immunosuppression drug dosage tacrolimus azathioprine
Harrison's Principles of Internal Medicine, Twenty First Edition
Page 7285
GradeResponse
GradeResponse
Here is the full breakdown with drug dosages for all major post-lung transplant complications:
Post-Lung Transplant Complications — Management & Drug Dosages
PART 1: IMMUNOSUPPRESSION (Baseline — Prevents Rejection)
Standard triple therapy (Harrison's, p. 7285):
Calcineurin Inhibitors (CNIs)
| Drug | Dose | Target Trough Level |
|---|---|---|
| Tacrolimus (preferred) | Start 0.05–0.1 mg/kg/day PO in 2 divided doses | Early: 10–15 ng/mL; Late (>1 yr): 5–10 ng/mL |
| Cyclosporine (alternative) | Start 3–5 mg/kg/day PO in 2 divided doses | Early: 250–350 ng/mL; Late: 100–200 ng/mL |
Antiproliferative Agents
| Drug | Dose | Notes |
|---|---|---|
| Mycophenolate mofetil (MMF) (preferred) | 1000–1500 mg PO BID | Monitor CBC for leukopenia |
| Azathioprine (alternative) | 1–2 mg/kg/day PO | Check TPMT enzyme level before starting |
| Sirolimus / Everolimus | Sirolimus: 1–5 mg/day (trough 5–15 ng/mL) | Avoid early post-op (impairs anastomotic healing); used later if CNI nephrotoxicity |
Corticosteroids
| Drug | Phase | Dose |
|---|---|---|
| Methylprednisolone | Intraoperative | 500 mg IV at reperfusion |
| Prednisone | Early post-op | 0.5–1 mg/kg/day, taper over weeks |
| Prednisone | Maintenance | 5–10 mg/day PO |
Induction Therapy (High-risk patients)
| Drug | Dose |
|---|---|
| Basiliximab | 20 mg IV on Day 0 and Day 4 |
| Antithymocyte globulin (ATG) | 1.5 mg/kg/day IV × 3–5 days |
PART 2: NON-INFECTIOUS COMPLICATIONS — MANAGEMENT & DRUGS
Primary Graft Dysfunction (PGD)
| Intervention | Details |
|---|---|
| Lung-protective ventilation | Tidal volume 6 mL/kg IBW, PEEP titration |
| Inhaled nitric oxide | 10–40 ppm (reduces pulmonary vascular resistance) |
| Inhaled Epoprostenol | 25–50 ng/kg/min via nebulizer (alternative to iNO) |
| ECMO | Veno-venous ECMO if refractory (PaO₂:FiO₂ < 100) |
| Methylprednisolone | 1 g IV × 3 days (some centers) |
Acute Cellular Rejection (ACR)
| Drug | Dose |
|---|---|
| Methylprednisolone (first-line) | 500–1000 mg IV daily × 3 days |
| Prednisone (oral taper after pulse) | 1 mg/kg/day, tapering over 2–4 weeks back to baseline |
| Optimize CNI trough | Ensure tacrolimus 12–15 ng/mL |
Antibody-Mediated Rejection (AMR)
| Drug | Dose |
|---|---|
| Methylprednisolone | 500–1000 mg IV × 3 days |
| Plasmapheresis | 5–7 sessions (removes donor-specific antibodies) |
| IVIG | 2 g/kg total (divided over 2–5 days; max 1 g/kg/day) |
| Rituximab | 375 mg/m² IV weekly × 1–4 doses (anti-CD20; depletes B cells) |
| Bortezomib | 1.3 mg/m² IV/SC on Days 1, 4, 8, 11 (targets plasma cells) |
| Eculizumab | 900 mg IV weekly × 4 then 1200 mg every 2 weeks (complement inhibitor; refractory cases) |
Chronic Lung Allograft Dysfunction (CLAD) / BOS
| Drug | Dose | Notes |
|---|---|---|
| Azithromycin (first-line) | 250 mg PO 3×/week or 500 mg 3×/week | Anti-inflammatory + immunomodulatory; stabilizes FEV₁ |
| Montelukast | 10 mg PO daily | May slow BOS progression |
| Pirfenidone | 267 mg TID increasing to 801 mg TID | Particularly for RAS phenotype |
| Switch tacrolimus → Everolimus/Sirolimus | Target trough 5–10 ng/mL | mTOR inhibitors may slow fibroproliferation |
| Extracorporeal Photopheresis (ECP) | Typically 2 consecutive days/month | Immunomodulatory; steroid-sparing |
| Augment immunosuppression | Pulse steroids, optimize CNI levels | |
| Re-transplantation | — | Last resort for end-stage CLAD |
Post-Transplant Hypertension (CNI-induced)
| Drug | Dose |
|---|---|
| Amlodipine | 5–10 mg PO daily (preferred; also reduces tacrolimus breakdown) |
| Nifedipine | 30–90 mg PO daily |
| Avoid ACE inhibitors if renal dysfunction | — |
Post-Transplant Diabetes (PTDM)
| Drug | Notes |
|---|---|
| Insulin (preferred early) | Basal-bolus regimen; adjust to glucose 140–180 mg/dL |
| Metformin | 500–2000 mg/day PO (if eGFR > 45) |
| Minimize prednisone dose | Key non-pharmacologic intervention |
Osteoporosis
| Drug | Dose |
|---|---|
| Calcium | 1000–1200 mg/day PO (in divided doses) |
| Vitamin D | 800–2000 IU/day PO |
| Alendronate | 70 mg PO weekly |
| Zoledronic acid | 5 mg IV annually |
GERD (reduces aspiration-induced CLAD)
| Drug | Dose |
|---|---|
| Pantoprazole / Omeprazole | 40 mg PO daily or BID |
| Metoclopramide | 10 mg PO TID-QID (if gastroparesis) |
| Fundoplication | Surgical option in refractory cases |
PART 3: INFECTIOUS COMPLICATIONS — PROPHYLAXIS & TREATMENT
CMV
| Setting | Drug | Dose | Duration |
|---|---|---|---|
| Universal prophylaxis | Valganciclovir | 900 mg PO daily (reduce dose if CrCl < 60) | 6–12 months (longer for D+/R−) |
| Active CMV disease (treatment) | Valganciclovir (mild-moderate) | 900 mg PO BID × 3 weeks | Until CMV PCR undetectable |
| Severe/pneumonitis | Ganciclovir IV | 5 mg/kg IV BID × 14–21 days | + IVIG 500 mg/kg every other day × 10 doses (some protocols) |
| Ganciclovir-resistant CMV | Foscarnet | 60 mg/kg IV q8h or 90 mg/kg IV q12h | Monitor renal function closely |
| Maribavir (newer agent) | 400 mg PO BID | Refractory/resistant CMV; approved 2021 |
Pneumocystis jirovecii Pneumonia (PJP)
| Setting | Drug | Dose |
|---|---|---|
| Prophylaxis (lifelong or ≥ 1 year) | TMP-SMX (Co-trimoxazole) | 1 SS tab (80/400 mg) PO daily OR 1 DS tab (160/800 mg) 3×/week |
| Alternative prophylaxis | Dapsone | 100 mg PO daily (check G6PD first) |
| Alternative prophylaxis | Atovaquone | 1500 mg PO daily (with food) |
| Alternative prophylaxis | Inhaled pentamidine | 300 mg via nebulizer monthly |
| Active PJP treatment | TMP-SMX | 15–20 mg/kg/day IV or PO (TMP component) in 3–4 divided doses × 21 days |
| Adjunctive (if PaO₂ < 70 mmHg) | Prednisone | 40 mg PO BID × 5 days → 40 mg daily × 5 days → 20 mg daily × 11 days |
Aspergillus (Fungal)
| Setting | Drug | Dose | Notes |
|---|---|---|---|
| Prophylaxis | Voriconazole | 200 mg PO BID | Monitor tacrolimus level (CYP3A4 inhibition → reduce tacrolimus by 50–75%) |
| Prophylaxis (alternative) | Itraconazole | 200 mg PO BID | Check serum levels |
| Prophylaxis (alternative) | Inhaled Amphotericin B | 25 mg inhaled BID (lipid formulation) | Minimal systemic absorption |
| Prophylaxis (alternative) | Micafungin | 50 mg IV daily (during early post-op period) | — |
| Invasive Aspergillosis (treatment) | Voriconazole | Load: 6 mg/kg IV q12h × 2 doses; Maintenance: 4 mg/kg IV q12h → 200 mg PO BID | Trough target: 1–5.5 mcg/mL; Duration ≥ 6–12 weeks |
| Alternative treatment | Isavuconazole | 200 mg IV/PO q8h × 6 doses (load), then 200 mg daily | Fewer drug interactions than voriconazole |
| Alternative treatment | Liposomal Amphotericin B | 3–5 mg/kg IV daily | For azole-intolerant/resistant cases |
| Salvage | Caspofungin | 70 mg IV load, then 50 mg IV daily | Combination with voriconazole in refractory cases |
Candida
| Setting | Drug | Dose |
|---|---|---|
| Invasive candidiasis (treatment) | Caspofungin | 70 mg IV load, then 50 mg IV daily |
| Step-down / less severe | Fluconazole | 400–800 mg PO/IV daily (species permitting) |
| Alternative | Micafungin | 100–150 mg IV daily |
Bacterial Infections (Post-Transplant Pneumonia)
Treatment is guided by culture results, but empiric regimens:
| Setting | Empiric Regimen | Notes |
|---|---|---|
| Early HAP/VAP | Piperacillin-tazobactam 4.5 g IV q6h ± Vancomycin 15–20 mg/kg IV q8–12h | Cover gram-negatives + MRSA |
| Pseudomonas risk | Cefepime 2 g IV q8h or Meropenem 1–2 g IV q8h | De-escalate per culture |
| Burkholderia cepacia (CF patients) | Meropenem + TMP-SMX ± Minocycline | Inherently resistant to many antibiotics |
| MRSA | Vancomycin 15–20 mg/kg IV q8–12h (trough/AUC-guided) OR Linezolid 600 mg IV/PO BID | — |
Viral — HSV/VZV
| Setting | Drug | Dose |
|---|---|---|
| HSV/VZV prophylaxis | Acyclovir | 400–800 mg PO BID–TID |
| Alternative | Valacyclovir | 500 mg–1 g PO daily |
| Active HSV (moderate) | Acyclovir | 5 mg/kg IV q8h or 400 mg PO 5×/day × 7–10 days |
| Active VZV/disseminated | Acyclovir | 10–12 mg/kg IV q8h × 7–10 days |
EBV / PTLD
| Setting | Drug | Dose |
|---|---|---|
| PTLD (first-line) | Reduce immunosuppression | Reduce/stop antiproliferative; reduce CNI by 25–50% |
| CD20+ PTLD | Rituximab | 375 mg/m² IV weekly × 4 doses |
| Refractory PTLD | R-CHOP chemotherapy | Standard lymphoma regimen |
| EBV prophylaxis monitoring | EBV PCR surveillance | Pre-emptive reduction of immunosuppression if rising viral load |
Mycobacterial — Latent TB (Pre-transplant treatment, continued post-transplant)
| Drug | Dose | Duration |
|---|---|---|
| Isoniazid (INH) | 300 mg PO daily + Pyridoxine 25–50 mg/day | 9 months |
| Rifampin (alternative; avoid if on CNI — major drug interaction) | 600 mg PO daily | 4 months |
KEY DRUG INTERACTION ALERT
Azole antifungals (voriconazole, itraconazole, fluconazole) are potent CYP3A4 inhibitors — they significantly increase tacrolimus and cyclosporine levels. When starting an azole, reduce tacrolimus dose by 50–75% and recheck levels in 48–72 hours.Rifampin is a potent CYP3A4 inducer — it dramatically lowers CNI levels and should generally be avoided; use rifabutin if needed.
QUICK REFERENCE SUMMARY TABLE
| Complication | Drug | Key Dose |
|---|---|---|
| Maintenance immunosuppression | Tacrolimus + MMF + Prednisone | 0.05–0.1 mg/kg/day + 1500 mg BID + 5–10 mg/day |
| Acute rejection | Methylprednisolone | 500–1000 mg IV × 3 days |
| AMR | IVIG + Rituximab + Plasmapheresis | 2 g/kg + 375 mg/m² + 5–7 sessions |
| BOS/CLAD | Azithromycin | 250–500 mg 3×/week |
| CMV prophylaxis | Valganciclovir | 900 mg PO daily |
| CMV treatment | Ganciclovir IV | 5 mg/kg IV BID |
| PJP prophylaxis | TMP-SMX | 1 SS tab daily |
| PJP treatment | TMP-SMX | 15–20 mg/kg/day (TMP) × 21 days |
| Aspergillus prophylaxis | Voriconazole | 200 mg PO BID |
| Invasive Aspergillosis | Voriconazole | 6 mg/kg q12h × 2 doses → 4 mg/kg q12h |
| HSV/VZV prophylaxis | Acyclovir | 400–800 mg PO BID |
| PTLD | Rituximab | 375 mg/m² weekly × 4 |
| Osteoporosis | Zoledronic acid | 5 mg IV annually |
| GERD | Pantoprazole | 40 mg PO daily |
This is a shared conversation. Sign in to Orris to start your own chat.